Funded Projects
Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.
Project # | Project Title | Research Focus Area | Research Program | Administering IC | Institution(s) | Investigator(s) | Location(s) | Year Awarded |
---|---|---|---|---|---|---|---|---|
3U01DA055352-03S1
Show Summary |
1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium | Enhanced Outcomes for Infants and Children Exposed to Opioids | HEALthy Brain and Child Development Study (HBCD) | NIDA | ARKANSAS CHILDREN'S HOSPITAL RES INST | OU, XIAWEI (contact); ACHESON, ASHLEY; MCKELVEY, LORRAINE M | Little Rock, AR | 2023 |
NOFO Title: Notice of Special Interest (NOSI): HEAL Initiative: Biospecimen Collection in Pregnancy
NOFO Number: NOT-DA-23-005 Summary: Opioid use during pregnancy is associated with adverse outcomes for pregnant individuals and offspring. The mechanisms through which these outcomes arise and the consequences of prenatal opioid exposure on child health and development remain largely unexplored. The HEALthy Brain and Child Development (HBCD) Study is a nationwide longitudinal prospective study of early child development that will assess a broad spectrum of biological, behavioral, social, and health factors among 7,500 pregnant women and their children from pregnancy to mid-childhood. This supplement will expand the biospecimen collection of the HBCD protocol at the University of North Carolina at Chapel Hill to include delivery specimens (placenta, cord tissue, and cord blood). This will provide an unprecedented resource-generating opportunity for the larger scientific community to comprehensively evaluate mechanisms that mediate the connection between substance use during pregnancy and adverse neonatal, infant, and/or maternal health outcomes and inform innovative preventive strategies. |
||||||||
3UH3DA047714-04S1
Show Summary |
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | WEST VIRGINIA UNIVERSITY | REZAI, ALI R | Morgantown, WV | 2023 |
NOFO Title: Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder
NOFO Number: PA-20-272 Summary: Novel treatments for opioid use disorder are critically needed as the addiction and overdose crises continue. Neuromodulation is a promising supplemental treatment to standard care. The overarching project seeks to evaluate low-intensity focused ultrasound that targets the nucleus accumbens, a primary component of the brain’s reward neurocircuitry. This supplement will expand the number of participants in part of the study and will increase the project’s overall impact consistent with the original objectives and aims of the parent grant. |
||||||||
1R61DA059169-01
Show Summary |
Leveraging Data to Action: Accelerating Emergency Department OUD Care by Improving Data Access and Infrastructure | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | YALE UNIVERSITY | VENKATESH, ARJUN KRISHNA (contact); HAWK, KATHRYN; TAYLOR, RICHARD ANDREW | New Haven, CO | 2023 |
NOFO Title: HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional)
NOFO Number: RFA-DA-23-057 Summary: Emergency departments (EDs) are key settings for identifying and treating opioid use disorder (OUD), but EDs are underused for this purpose. This project aims to develop a data system that automates and integrates electronic health record and administrative data from EDs into the Clinical Emergency Department Registry, partnering with the American College of Emergency Physicians. The research will assess the digital readiness of ED systems before developing and deploying the enhanced ED OUD data infrastructure. This research aims to guide near-real time hospital quality improvement initiatives, toward development of a web-based, near-real time dashboard that can be used in EDs across the country. |
||||||||
1R61DA059027-01
Show Summary |
A Multi-Team System Implementation Strategy to Improve Buprenorphine Adherence for Patients who Initiate Treatment in the Emergency Department | Translation of Research to Practice for the Treatment of Opioid Addiction | Optimizing the Quality, Reach, and Impact of Addiction Services | NIDA | UNIVERSITY OF CALIFORNIA AT DAVIS | HENRY, STEPHEN G (contact); MOULIN, AIMEE; TU, SHIN-PING | Davis, CA | 2023 |
NOFO Title: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-23-053 Summary: There is an urgent need to identify and rapidly apply strategies to expand treatment for opioid use disorder, particularly among low-income patients. This project will develop and test a novel implementation strategy that uses ongoing community partnerships designed to improve care coordination for patients who start buprenorphine treatment for opioid use disorder in the emergency department and are then referred to primary care for ongoing treatment. |
||||||||
1R43HD112219-01A1
Show Summary |
Targeted Temperature Modulation with Smart Radiometric Monitoring for Effective and Long-Lasting Opioid-Free Pelvic Pain Relief: A Novel Low-Cost, Portable, Tampon-Sized Thermal Transfer Device | Cross-Cutting Research | Small Business Programs | NICHD | H3PELVIC THERAPY SYSTEMS, INC. | LYON, ZACHARY W | Lewisville, NC | 2023 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-23-006 Summary: Pelvic pain (PP) includes more than 20 different painful and debilitating conditions, such as urinary tract infections, menstrual cramps, endometriosis, overactive bladder, and interstitial cystitis, and affects millions of people. Globally, pelvic pain affects 1 in 5 women and 1 in 12 men. This project will develop an instrument to monitor and treat pain-associated temperature changes in the pelvic region to reduce chronic pelvic pain. This novel system is intended to be used at home with personalized settings. |
||||||||
1UG3DA058552-01
Show Summary |
Development of a Potent and Selective NaV1.8 Inhibitor for the Treatment of Acute and Chronic Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | SITEONE THERAPEUTICS, INC. | HUNTER, JOHN CURETON (contact); MULCAHY, JOHN VINCENT | South San Francisco, CA | 2023 |
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
NOFO Number: PAR-20-092 Summary: The sodium channel NaV1.8 is a promising target for the development of effective, non-addictive pain medications. Recent evidence from clinical studies indicates that medications that target NaV1.8 are effective at managing postoperative, neuropathic, and inflammatory pain, but with side effects and prohibitively high cost. This project will test the safety and compatibility in the body of an NaV1.8-targeted molecule, toward developing an effective, non-addictive, once daily oral medication for the treatment of acute postsurgical pain and chronic neuropathic. |
||||||||
1R21NS132565-01
Show Summary |
Discovery of the Novel Targets for Post-Traumatic Headache | Preclinical and Translational Research in Pain Management | Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain | NINDS | WASHINGTON UNIVERSITY | CAO, YUQING | Saint Louis, MO | 2023 |
NOFO Title: Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)
NOFO Number: RFA-TR-22-011 Summary: Chronic post-traumatic headache (PTH) is highly debilitating, poorly understood, and difficult to treat. This project aims to identify proteins located in the membrane of certain neurons that are critical for the development, maintenance, and/or resolution of PTH. These proteins may be targets for novel treatment approaches that are nonaddictive and have minimal side effects. |
||||||||
1R43DA058614-01
Show Summary |
Combination Therapeutic for Chronic Opioid Use Disorder Relapse | Cross-Cutting Research | Small Business Programs | NIDA | APHIOS CORPORATION | CASTOR, TREVOR P | Woburn, MA | 2023 |
NOFO Title: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-22-176 Summary: Side effects from taking the opioid receptor blocker naltrexone make it difficult for patients to adhere to treatment with this medication for opioid use disorder. Cannabidiol (CBD), a bioactive ingredient of cannabis, is not an opioid and is non-psychoactive. Previous research shows that CBD blocks opioid-seeking behaviors, craving, and withdrawal. This project will develop tiny particles containing CBD and low-dose naltrexone. The research will determine if this combined version of CBD and naltrexone helps people stay in treatment and prevents relapse without problematic side effects. |
||||||||
1U24DA058673-01
Show Summary |
Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long-Term Opioid Therapy - Yale Resource Center (MIRHIQL-YRC) | Clinical Research in Pain Management | Reducing Opioid-Related Harms to Treat Chronic Pain (IMPOWR and MIRHIQL) | NIDA | YALE UNIVERSITY | BECKER, WILLIAM C (contact); BLACK, ANNE C; DEBAR LYNN L; EDMOND, SARA; ESSERMAN, DENISE | New Haven, CT | 2023 |
NOFO Title: HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL): Resource Center (U24- Clinical Trial Optional)
NOFO Number: RFA-DA-23-042 Summary: Decreasing opioid dosing faster than advised by clinical recommendations often leaves chronic pain unaddressed and may increase the risk of overdose and suicide compared to continuing long-term opioid treatment. The MIRHIQL Resource Center will provide infrastructure support for the network as well as create a risk-benefit decision tool to help providers determine when opioids should be continued as prescribed, tapered, or tapered/discontinued. The center will first develop and validate a clinical definition for individuals who take long-term opioids, then study long-term outcomes in participants who receive treatment in primary care settings. This research will partner with many groups including individuals with lived experience, community health care providers who treat such individuals, research scientists, bioethicists, and professional societies |
||||||||
5U54DA049110-04
Show Summary |
Data Center for Acute to Chronic Pain Biosignatures | Clinical Research in Pain Management | Acute to Chronic Pain Signatures Program | NIDA | JOHNS HOPKINS UNIVERSITY | LINDQUIST, MARTIN (contact); WAGER, TOR D | Baltimore, MD | 2023 |
NOFO Title: Notice of Special Interest (NOSI): Encourage Eligible NIH HEAL Initiative Awardees to Apply for Administrative Supplements to Support Career Enhancement Related to Clinical Research on Pain
NOFO Number: NOT-NS-22-087 Summary: Understanding the mechanisms underlying the transition to chronic pain is key to mitigating the dual epidemics of chronic pain and opioid use in the United States. As part of the National Institutes of Health-funded Acute to Chronic Pain Signatures Program, the Data Integration and Resource Center aims to This project will support a post-doctoral trainee to develop the skills and knowledge needed to pursue a successful career in clinical pain research. The research will involve integrating imaging, physiology, -omics, behavioral, and clinical data to develop biosignatures for the transition from acute to chronic pain, toward understanding how the nervous and immune systems affect post-surgical pain and opioid use. |
||||||||
1R01DA059152-01
Show Summary |
POPI: Placenta, Opioids and Perinatal Implications | Enhanced Outcomes for Infants and Children Exposed to Opioids | The Biology of Opioid Exposure During Pregnancy and Effects on Early Neuro-Behavioral Development | NIDA | UNIVERSITY OF KENTUCKY | MESSAOUDI, ILHEM (contact); O'BRIEN, JOHN M | Lexington, KY | 2023 |
NOFO Title: HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-HD-23-034 Summary: Opioid use during pregnancy is associated with harmful health outcomes for infants including preterm birth, neonatal opioid withdrawal syndrome, and brain-related problems. This project will carry out an in-depth investigation of the effects of opioid use during pregnancy including changes to health of the placenta, inflammation in the fetus, as well as behavioral and movement-related outcomes during the first year of life. This research will contribute to fundamental knowledge about how the placenta and brain work together as well as identify new strategies for diagnosing, treating, and preventing opioid harm to the fetus and mother. |
||||||||
3U01DA055363-03S1
Show Summary |
12/24 The HEALthy Brain and Child Development National Consortium | Enhanced Outcomes for Infants and Children Exposed to Opioids | HEALthy Brain and Child Development Study (HBCD) | NIDA | OREGON HEALTH & SCIENCE UNIVERSITY | SULLIVAN, ELINOR L (contact); GRAHAM, ALICE M; NAGEL, BONNIE J | Portland, OR | 2023 |
NOFO Title: Notice of Special Interest (NOSI): HEAL Initiative: Biospecimen Collection in Pregnancy
NOFO Number: NOT-DA-23-005 Summary: Opioid use during pregnancy is associated with adverse outcomes for pregnant individuals and offspring. The mechanisms through which these outcomes arise and the consequences of prenatal opioid exposure on child health and development remain largely unexplored. The HEALthy Brain and Child Development (HBCD) Study is a nationwide longitudinal prospective study of early child development that will assess a broad spectrum of biological, behavioral, social, and health factors among 7,500 pregnant women and their children from pregnancy to mid-childhood. This supplement will expand the biospecimen collection of the HBCD protocol at the University of North Carolina at Chapel Hill to include delivery specimens (placenta, cord tissue, and cord blood). This will provide an unprecedented resource-generating opportunity for the larger scientific community to comprehensively evaluate mechanisms that mediate the connection between substance use during pregnancy and adverse neonatal, infant, and/or maternal health outcomes and inform innovative preventive strategies. |
||||||||
1UG3DA059286-01
Show Summary |
A Therapeutic Agent to Lower the Level of Synthetic Opioids in the Body | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | CLEAR SCIENTIFIC, LLC | LI, XINHUA | Cambridge, MA | 2023 |
NOFO Title: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
NOFO Number: PAR-22-200 Summary: There is an urgent need for longer acting opioid overdose reversal medications to treat acute fentanyl intoxication and overdose. This project will develop a novel molecule (CS-1103) that sticks to fentanyl and removes it from the body. Previous research with animal models shows that CS-1103 has several features that make it attractive for a new medication. It can reverse fentanyl-induced respiratory depression, preventing another overdose; work in combination with naloxone; and appears to be safe and well-tolerated. The research will continue exploration of CS-1103 toward testing CS-1103 in human research participants. |
||||||||
1UG3NS130592-01A1
Show Summary |
Sensory Phenotyping to Enhance Neuropathic Pain Drug Development | Clinical Research in Pain Management | Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions | NINDS | BETH ISRAEL DEACONESS MED CENT | FREEMAN, ROY (contact); EDWARDS, ROBERT R; GEWANDTER, JENNIFER | Boston, MA | 2023 |
NOFO Title: HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)
NOFO Number: RFA-NS-22-050 Summary: Neuropathic pain is a chronic and difficult to treat condition that affects people in different ways. This project aims to personalize treatments based on individual pain profiles. The research will develop an inexpensive test using a technique called quantitative sensory testing to predict how a patient will respond to two common pain medications. The research will also look for other factors in blood that enhance the accuracy of these predictions. |
||||||||
1UG3AR083838-01
Show Summary |
Improving Function and Reducing Opioid Use for Patients with Chronic Low Back Pain in Rural Communities Through Improved Access to Physical Therapy Using Telerehabilitation | Clinical Research in Pain Management | Prevention and Management of Chronic Pain in Rural Populations | NIAMS | JOHNS HOPKINS UNIVERSITY | SKOLASKY, RICHARD L (contact); MCLAUGHLIN, KEVIN | Baltimore, MD | 2023 |
NOFO Title: HEAL Initiative: Prevention and Management of Chronic Pain in Rural Populations (UG3/UH3, Clinical Trials Required)
NOFO Number: RFA-NR-23-001 Summary: Physical therapy is the recommended treatment for patients with low back pain and is a cost-effective method for improving pain and reducing disability. However, only 7-13% of patients receive physical therapy services. Access is particularly limited in rural communities due to lack of provider availability, transportation, and missed work time. These factors have contributed to more low back pain-related disability and opioid use among rural populations. Physical therapy delivered through telemedicine may improve access by reducing patient-reported barriers. This randomized clinical trial will compare an innovative, patient-centered telemedicine version of physical therapy to a currently used psychologically based educational approach for rural patients with chronic low back pain. The research will match individual patients to a treatment approach based on their psychosocial risk of poor outcomes. |
||||||||
1R18EB035004-01
Show Summary |
Point of Care Diagnostic for Sickle Cell Disease | Preclinical and Translational Research in Pain Management | Translating Discoveries into Effective Devices to Treat Pain | NIBIB | DUKE UNIVERSITY | WAX, ADAM | Durham, NC | 2023 |
NOFO Title: HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)
NOFO Number: RFA-EB-22-002 Summary: People with sickle cell disease often experience episodes of severe pain (vaso-occlusive crisis) that are caused by the abnormal red blood cells and frequently result in opioid use. Tools that can identify and measure the degree of such a crisis early on could allow clinicians to pre-emptively disrupt this process. This project aims to develop a rapid, automated screening technology for evaluating red blood cells that allows assessment of patients at risk of pain crisis right in their health care provider’s office. |
||||||||
1UG3NS131304-01
Show Summary |
Development of Positive TMEM97 Modulators for Treating Neuropathic Pain | Preclinical and Translational Research in Pain Management | Development and Optimization of Non-Addictive Therapies to Treat Pain | NINDS | NUVONURO, INC. | MARTIN, STEPHAN | Austin, TX | 2023 |
NOFO Title: HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
NOFO Number: RFA-NS-21-010 Summary: Neuropathic pain is a debilitating and complex medical condition for which safe and non-addictive treatment options are urgently needed. This project aims to develop new strategies for treating neuropathic pain by controlling the activity of transmembrane protein 97 (TMEM97), also known as the sigma 2 receptor, which has been shown to relieve pain in an animal model of neuropathic pain. The research aims to develop a new molecule that increases TMEM97 activity and is safe for human use, toward obtaining approval from the U.S. Food and Drug Administration for Phase I clinical testing. |
||||||||
2R44DA048689-02
Show Summary |
Beacon-OUD: Behavioral Economic Screening Tool of Opioid Use Disorder (OUD) for Use in Clinical Practice | Cross-Cutting Research | Small Business Programs | NIDA | BEAM DIAGNOSTICS, INC. | SNIDER, SARAH EMILY | Roanoke, VA | 2023 |
NOFO Title: PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-21-259 Summary: Current clinical screening measures for opioid misuse are underused and susceptible to bias. This project will develop Beacon-OUD, a digital opioid misuse assessment. The tool generates an automated, standardized score, preventing potential judgements related to patient’s status and circumstances, limiting stigma. The research will further advance Beacon-OUD into a commercial product for use both as a stand-alone tool and as an electronic health record-integrated solution to encourage objective opioid misuse screening in large health care systems. |
||||||||
2R44MD015912-03
Show Summary |
Clinical Optimization of Ultrasonic Drug Delivery Technologies for Underserved Minority U.S. Veterans in Chronic Pain | Cross-Cutting Research | Small Business Programs | NIMHD | ZETROZ SYSTEMS, LLC | LEWIS, GEORGE KENNETH | Trumbull, CT | 2023 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)
NOFO Number: RFA-NS-20-010 Summary: Osteoarthritis is one of the most common joint diseases affecting Americans. Osteoarthritis is particularly high among veterans with a service-related disability. This project will develop and refine a wireless ultrasound device that increases the penetration of over-the-counter pain medications into the body, which is expected to reduce pain. The research will conduct safety and clinical testing toward commercializing this technology. |
||||||||
1R01DA058620-01
Show Summary |
Sequential Trial of Adding Buprenorphine, Cognitive Behavioral Treatment, and Transcranial Magnetic Stimulation to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain (ACTION) | Clinical Research in Pain Management | Reducing Opioid-Related Harms to Treat Chronic Pain (IMPOWR and MIRHIQL) | NIDA | MEDICAL UNIVERSITY OF SOUTH CAROLINA | BARTH, KELLY S (contact); BORCKARDT, JEFFREY J | Charleston, SC | 2023 |
NOFO Title: HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL) (R01 Clinical Trial Required)
NOFO Number: RFA-DA-23-041 Summary: There is little evidence available to guide clinical care for patients on long-term opioid therapy for whom risks exceed benefits. Given valid fears about both pain and withdrawal during decreased dosing (tapering), these individuals face challenges, including concerns about being abandoned by providers and uncertainty about the need to discontinue opioids. As such, these patients are hesitant to enroll voluntarily in opioid discontinuation research, further deepening the clinical evidence gap. This project will evaluate three effective and scalable interventions for individuals on long-term opioid therapy: (1) low-dose transdermal buprenorphine (without) of opioid withdrawal, (2) a brief cognitive behavioral intervention for pain, and (3) noninvasive brain stimulation. |
||||||||
1K23DA058751-01
Show Summary |
Building and Implementing Best Practices for Buprenorphine Initiation in the Setting of Fentanyl Use | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIDA | UNIVERSITY OF WASHINGTON | BHATRAJU, ELENORE | Seattle, WA | 2023 |
NOFO Title: HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required)
NOFO Number: PAS-22-207 Summary: This project provides protected time for training and research activities that are required for an independent scientific career in delivering evidence-based treatments for people with opioid use disorder. The increasing presence of fentanyl in the drug supply creates challenges for the use of buprenorphine, because both patients and physicians want to avoid causing withdrawal. This research will interview both patients and physicians to understand their concerns and experiences and work with them to develop a buprenorphine induction toolkit to help balance the advantages of buprenorphine treatment against concerns about the potential presence of unknown fentanyl. |
||||||||
1R01HD113032-01
Show Summary |
Predicting Neonatal Health Outcomes From Placental and Fetal Brain Extracellular Vesicles in Pregnant Opioid Users | Enhanced Outcomes for Infants and Children Exposed to Opioids | The Biology of Opioid Exposure During Pregnancy and Effects on Early Neuro-Behavioral Development | NICHD | UNIVERSITY OF WASHINGTON | VOJTECH, LUCIA N (contact); CHIU, DANIEL T | Seattle,WA | 2023 |
NOFO Title: HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-HD-23-037 Summary: Opioid use during pregnancy is associated with significant harmful health outcomes for infants including preterm birth, neonatal opioid withdrawal syndrome (NOWS), and impaired brain-related problems. Not all infants exposed to opioids develop NOWS, and there is a need for better diagnostic tests. This project will study specialized cell structures called vesicles that are released from the placenta, fetal brain, and central nervous system to communicate information about health of the fetus and placenta. This research on vesicles will be combined with data about NOWS diagnosis up to 1 month after birth. The research aims to generate molecular indicators (biomarkers) that predict which newborns develop NOWS, toward guiding safe and effective treatment for these newborns. |
||||||||
5U24DA055325-02
Show Summary |
The HEALthy Brain and Child Development National Consortium Administrative Core | Enhanced Outcomes for Infants and Children Exposed to Opioids | HEALthy Brain and Child Development Study (HBCD) | NIDA | UNIVERSITY OF CALIFORNIA, SAN DIEGO | CHAMBERS, CHRISTINA (contact); NELSON, CHARLES ALEXANDER | La Jolla, CA | 2023 |
NOFO Title: Notice of Special Interest (NOSI): HEAL Initiative: Biospecimen Collection in Pregnancy
NOFO Number: NOT-DA-23-005 Summary: Opioid use during pregnancy is associated with adverse outcomes for pregnant individuals and offspring. The mechanisms through which these outcomes arise and the consequences of prenatal opioid exposure on child health and development remain largely unexplored. The HEALthy Brain and Child Development (HBCD) Study is a nationwide longitudinal prospective study of early child development that will assess a broad spectrum of biological, behavioral, social, and health factors among 7,500 pregnant women and their children from pregnancy to mid-childhood. This supplement will expand the biospecimen collection of the HBCD protocol at the University of North Carolina at Chapel Hill to include delivery specimens (placenta, cord tissue, and cord blood). This will provide an unprecedented resource-generating opportunity for the larger scientific community to comprehensively evaluate mechanisms that mediate the connection between substance use during pregnancy and adverse neonatal, infant, and/or maternal health outcomes and inform innovative preventive strategies. |
||||||||
1UG3DA058439-01
Show Summary |
Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | CORIDEA, LLC | LEVIN, HOWARD (contact); COMER, SANDRA D; GUEDES, ALONSO; WAGENER, GEBHARD | New York, NY | 2023 |
NOFO Title: Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)
NOFO Number: PAR-20-279 Summary: Difficulty breathing is a hallmark symptom of an opioid-related overdose and can result in permanent brain injury or death within minutes. This project will develop a community-deployable Automated External Respiration System device that can restore and sustain breathing in people experiencing opioid-induced respiratory depression. The device stimulates the phrenic nerve in the chest that controls breathing until other medical interventions are available or the patient recovers. The research will develop and validate the automated external respiration system for testing in human research participants and ultimately aims to develop a system usable in a community setting. |
||||||||
1UG3NS128148-01A1
Show Summary |
Peripherally Restricted Non-Addictive Cannabinoids for Cancer Pain | Preclinical and Translational Research in Pain Management | Development and Optimization of Non-Addictive Therapies to Treat Pain | NINDS | UNIVERSITY OF CALIFORNIA LOS ANGELES | SPIGELMAN, IGOR (contact); CAHILL, CATHERINE M; FAULL, KYM FRANCIS; SCHMIDT, BRIAN L; SPOKOYNY, ALEXANDER MICHAEL | Los Angeles, CA | 2023 |
NOFO Title: HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
NOFO Number: RFA-NS-21-010 Summary: Oral cancer pain is debilitating and difficult to treat, in part because even the most effective available pain remedies are limited by side effects. Opioid-based pain medications have several side effects including dependence and tolerance, in which the body gets used to a medicine so that either more medicine is needed or different medicine is needed. Another side effect is hyperalgesia, in which people taking opioids become more sensitive to certain painful stimuli and may misuse the drugs and risk addiction. This project will evaluate lab-made versions of cannabinoid molecules known to block pain signals in nerve cells, but which cannot enter the brain to cause neurological side effects. The research aims to advance promising versions of the molecules to testing in human research participants. |